Incyte
Pays vs peer median
×0.70
-30% premium
Sample
3
low confidence
Last refreshed
2026-04-13
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2024 | EP262 and MRGPRX programs | Escient Pharmaceuticals | Atopic Dermatitis, Chronic Pruritus | phase_1 | $200M | $1.0B |
| 2024 | mds | Syndax Pharmaceuticals | mds | approved | $200M | $1.4B |
| 2024 | solid_tumors | MacroGenics | solid_tumors | phase_1 | $150M | $900M |
| 2023 | ATR | Mirati Therapeutics | Pancreatic | discovery | $46M | $490M |
| 2022 | STEAP1-101 | Akeso | RCC | phase_3 | $811M | $5.9B |
How this is computed
For each Incyte deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 0.633, clamped to [0.7, 1.5].